NASDAQ:JANX Janux Therapeutics Q2 2025 Earnings Report $23.29 +0.25 (+1.09%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Janux Therapeutics EPS ResultsActual EPS-$0.55Consensus EPS -$0.48Beat/MissMissed by -$0.07One Year Ago EPSN/AJanux Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.30 millionBeat/MissN/AYoY Revenue GrowthN/AJanux Therapeutics Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time4:00PM ETUpcoming EarningsJanux Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Tuesday, November 4, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Janux Therapeutics Earnings HeadlinesJanux Therapeutics initiated with a Buy at GuggenheimSeptember 4 at 2:18 AM | msn.comBTIG Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)August 27, 2025 | theglobeandmail.comFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your spot for FREE.September 4 at 2:00 AM | Crypto 101 Media (Ad)Piper Sandler Initiates Coverage of Janux Therapeutics (JANX) with Overweight RecommendationAugust 20, 2025 | msn.comJanux Therapeutics initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comPiper starts Janux Therapeutics with an Overweight on ‘best-in-class’ potentialAugust 19, 2025 | msn.comSee More Janux Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email. Email Address About Janux TherapeuticsJanux Therapeutics (NASDAQ:JANX) is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX. Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration. By activating key pathways of the innate immune response, these candidates aim to recruit and amplify antitumor T-cell activity while minimizing systemic exposure. Janux’s pipeline is advancing through early-stage clinical trials to evaluate safety, tolerability and preliminary signals of efficacy in a variety of solid tumors. Based in San Diego, Janux leverages collaborations with contract research organizations and academic centers to support manufacturing and clinical development. The company’s leadership team comprises experienced immuno-oncology researchers and drug developers with backgrounds in biologics, formulation science and regulatory strategy. Janux continues to build its infrastructure and partnerships to accelerate the translation of its TLR agonists from preclinical research into potential new treatment options for cancer patients.Written by Jeffrey Neal JohnsonView Janux Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ambarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised Guidance Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
